Skip to main content

Campylobacter Infection

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
ALFQPhase 11 trial
Active Trials
NCT05500417Completed59Est. Jan 2025
Fulcrum Therapeutics
1 program
ACE393PHASE_21 trial
Active Trials
NCT00859716Unknown72Est. Jul 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Fulcrum TherapeuticsACE393
Allergy TherapeuticsALFQ

Clinical Trials (2)

Total enrollment: 131 patients across 2 trials

ACE393-103 Vaccination Challenge Study

Start: Oct 2008Est. completion: Jul 200972 patients
Phase 2Unknown

Safety and Immunogenicity of CJCV2 With and Without ALFQ

Start: Sep 2022Est. completion: Jan 202559 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.